S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:GOSS

Gossamer Bio Stock Forecast, Price & News

$10.26
-0.78 (-7.07%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.10
$11.03
50-Day Range
$10.26
$14.07
52-Week Range
$7.04
$14.30
Volume
1.98 million shs
Average Volume
565,728 shs
Market Capitalization
$784.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.95
30 days | 90 days | 365 days | Advanced Chart
Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.


Gossamer Bio logo

About Gossamer Bio

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Headlines

Onxeo Continues to Strengthen its Board of Directors
November 23, 2021 |  finance.yahoo.com
Gossamer Bio (NASDAQ:GOSS) Price Target Raised to $16.00
November 9, 2021 |  americanbankingnews.com
Gossamer Bio Appoints CFO Bryan Giraudo To Addl. Role Of COO - Quick Facts
September 21, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
196
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.22 per share

Profitability

Net Income
$-243.36 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
70,347,000
Market Cap
$784.52 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

538th out of 1,390 stocks

Pharmaceutical Preparations Industry

251st out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

Is Gossamer Bio a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Gossamer Bio stock.
View analyst ratings for Gossamer Bio
or view top-rated stocks.

How has Gossamer Bio's stock price been impacted by Coronavirus (COVID-19)?

Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GOSS shares have decreased by 3.1% and is now trading at $10.26.
View which stocks have been most impacted by COVID-19
.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Gossamer Bio
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.02. During the same period last year, the business posted ($0.80) EPS.
View Gossamer Bio's earnings history
.

What price target have analysts set for GOSS?

5 analysts have issued 12-month price targets for Gossamer Bio's stock. Their forecasts range from $16.00 to $26.00. On average, they expect Gossamer Bio's share price to reach $22.50 in the next twelve months. This suggests a possible upside of 119.3% from the stock's current price.
View analysts' price targets for Gossamer Bio
or view top-rated stocks among Wall Street analysts.

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the following people:
  • Faheem Hasnain, Chairman, President & Chief Executive Officer
  • Bryan Giraudo, Chief Operating & Financial Officer
  • Richard Aranda, Chief Medical Officer
  • Laura Carter, Chief Scientific Officer (LinkedIn Profile)
  • Christian Waage, Secretary, General Counsel & Executive VP

What other stocks do shareholders of Gossamer Bio own?

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.06%), Boxer Capital LLC (3.22%), Emerald Mutual Fund Advisers Trust (2.08%), Emerald Advisers LLC (1.99%), Geode Capital Management LLC (1.31%) and Goldman Sachs Group Inc. (0.75%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Jakob Dupont, Laura Carter, Luisa Salter-Cid and Waage Christian.
View institutional ownership trends for Gossamer Bio
.

Which institutional investors are selling Gossamer Bio stock?

GOSS stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Boxer Capital LLC, Millennium Management LLC, BlackRock Inc., Royal Bank of Canada, Rafferty Asset Management LLC, and Nisa Investment Advisors LLC. Company insiders that have sold Gossamer Bio company stock in the last year include Bryan Giraudo, Laura Carter, and Luisa Salter-Cid.
View insider buying and selling activity for Gossamer Bio
or view top insider-selling stocks.

Which institutional investors are buying Gossamer Bio stock?

GOSS stock was acquired by a variety of institutional investors in the last quarter, including Wolverine Asset Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Eversept Partners LP, Moore Capital Management LP, Schonfeld Strategic Advisors LLC, Geode Capital Management LLC, and Cubist Systematic Strategies LLC. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, and Waage Christian.
View insider buying and selling activity for Gossamer Bio
or or view top insider-buying stocks.

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $10.26.

How much money does Gossamer Bio make?

Gossamer Bio has a market capitalization of $784.52 million. The company earns $-243.36 million in net income (profit) each year or ($3.26) on an earnings per share basis.

How many employees does Gossamer Bio have?

Gossamer Bio employs 196 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is www.gossamerbio.com.

Where are Gossamer Bio's headquarters?

Gossamer Bio is headquartered at 3013 SCIENCE PARK, SAN DIEGO CA, 92121.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 684-1300 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.